Skip to main content
Erschienen in: BMC Neurology 1/2018

Open Access 01.12.2018 | Case report

Intra-familial phenotypic heterogeneity in a Sudanese family with DARS2-related leukoencephalopathy, brainstem and spinal cord involvement and lactate elevation: a case report

verfasst von: Ashraf Yahia, Liena Elsayed, Arwa Babai, Mustafa A. Salih, Sarah Misbah El-Sadig, Mutaz Amin, Mahmoud Koko, Rayan Abubakr, Razaz Idris, Shaimaa Omer M.A. Taha, Salah A. Elmalik, Alexis Brice, Ammar Eltahir Ahmed, Giovanni Stevanin

Erschienen in: BMC Neurology | Ausgabe 1/2018

Abstract

Background

Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL, OMIM #611105) is a genetic disease of the central nervous system characterized by lower limb spasticity, cerebellar ataxia and involvement of the dorsal column. The disease is caused by mutations in the DARS2 gene but has never been reported in sub-Saharan Africa so far.

Case presentation

Two siblings, aged 18 years and 15 years, from a consanguineous family presented with pyramidal signs and symptoms since infancy and developmental delay. Whole exome sequencing of the proband identified two compound heterozygous variants (NM_018122.4:c.1762C > G and c.563G > A) in DARS2. Sanger sequencing confirmed the presence of the mutations and their segregation in trans in both patients and in their elder sister (aged 20 years), who showed only brisk reflexes and mild lower limb spasticity. Surprisingly, in contrast to her subtle clinical presentation, the elder sister had abnormal MRI features and serum lactate levels comparable to her ill sisters.

Conclusion

This report illustrates intra-familial phenotypic variation in LBSL and provides an example of a marked dissociation between the clinical and radiological phenotypes of the disease. This may have implications for the detection of mutation carriers in LBSL.
Abkürzungen
FLAIR
Fluid-attenuated inversion recovery
LBSL
Leukoencephalopathy, brainstem and spinal cord involvement and lactate elevation
MRI
Magnetic resonance imaging
OMIM
Online mendelian inheritance in man

Background

Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL, OMIM # 611105) is a genetic disease of the central nervous system characterized by lower limb spasticity, cerebellar ataxia and involvement of the dorsal column [1]. The clinical presentation is variable both in age at onset (early childhood or adulthood) and in associated features (learning difficulty, epilepsy, mental deterioration and others) [2]. Brain magnetic resonance imaging (MRI) shows diffuse cerebral white matter changes with signal abnormalities in the dorsal column and lateral corticospinal tracts in addition to spectroscopic findings of increased lactate [1].
LBSL is an autosomal recessive disease caused by mutations in DARS2 [3]. This gene, located on chromosome 1, has 17 exons and encodes the mitochondrial aspartyl-tRNA synthetase [3]. Defects in this gene in neurons impair the translation of mitochondrial mRNAs, leading to mitochondrial dysfunction and progressive cell loss [4]. We report here the identification of two compound heterozygous rare variants (NM_018122.4:c.1762C > G and c.563G > A) segregating in a Sudanese family with a wide clinical spectrum of LBSL and a marked dissociation between clinical and radiological phenotypes in one of the affected siblings.

Case presentation

Two siblings, aged 18 years and 15 years, from a Sudanese family (individuals 2043 and 2044) presented with pyramidal features since infancy (Table 1). Both patients were the outcome of uncomplicated normal vaginal deliveries and developed normally before the initial symptoms of the disease. Patient 2043 developed her symptoms from the age of 8 months after an attack of fever complicated by febrile convulsions. Initially, she manifested floppiness, which later turned into spasticity. Speech and walking were delayed (achieved at ages 3–4 and 6 years, respectively). At the age of 10 months she had three attacks of seizures, which were later controlled by carbamazepine. Spasticity progressed over time and currently the patient can only walk with support. In patient 2044, the disease started at the age of 4 months with initial floppiness followed by spasticity and delayed motor development as well, but without any history of convulsions or precipitating febrile illness. Speech developed normally. Her motor disability was analogous to that of her sister. Examination of the lower limbs showed severe spasticity, hyperreflexia and “up-going” plantar reflex in both patients. Whereas patient 2043 showed severe proximal and distal lower limb weakness, patient 2044 manifested only moderate proximal weakness. Due to the severe spasticity, heel on shin test was not applicable. Upon examination of the upper limbs, the two patients showed increased reflexes with normal tone and a normal finger-to-nose test. Ocular cerebellar signs (nystagmus, slow saccades and interrupted pursuit) were present in both patients. There were no extrapyramidal signs. Sensory nervous system and fundus examinations were normal. Both patients had normal cognitive functions and they were able to graduate from high school and attend university. Brain MRIs of patients 2043 and 2044 showed abnormal high signal intensity in the periventricular white matter and dentate nuclei bilaterally together with thinning of corpus callosum and cerebral and cerebellar atrophy (Fig. 1). Spinal MRI showed signal changes with dorsal spinal cord atrophic changes in both these affected sisters.
Table 1
Clinical characteristics of the described genetically affected siblings
Patient ID
2042
2043
2044
Gender
Female
Female
Female
Age at examination
20 years
18 years
15 years
Age at onset
8 months
4 months
Initial sign / symptom
Hypertonia and hyperreflexia detected during the sampling session
Floppiness
Floppiness
Delayed motor development
+
+
Delayed speech
+
Epilepsy
+
Cognitive impairment
Degree of motor disability
No functional handicap but signs at examination
Walk with support / unable to run
Walk with support / unable to run
Muscle wasting (UL & LL)
UL hypertonia
UL motor deficit
UL hyperreflexia
+
+
+
LL hypertonia
+
+
+
LL motor deficit
Severe
Moderate
LL hyperreflexia
+
+
+
Sensory impairment
Dysarthria
+
+
Ocular cerebellar signs
+
+
Dysmetria
Optic atrophy
Clinical summary
Pyramidal features
Pyramidal features, seizures, delayed speech, ocular cerebellar signs and dysarthria
Pyramidal features, ocular cerebellar signs and dysarthria
MRI changes in brain and spinal cord
+
+
+
Serum lactate level in mmol/L (reference range 0.5–2.2 mmol/L)
6.13
6.8
5.97
UL upper limb, LL lower limb, − absent, + present
Four first-degree relatives were assessed for inclusion as controls in the genetic analysis: the parents (2040 and 2041), an elder sister (2042), and a younger sister (2045). They underwent routine clinical examination to rule out the possibility of subtle abnormalities. The examination was normal in the parents and the younger sister. The elder sister showed brisk reflexes in both upper and lower limbs and mild spasticity in the lower limbs but no other clinically detectable abnormality (Table 1).
DNA was extracted from saliva samples. Whole exome sequencing was performed in the proband (patient 2043) and revealed two compound heterozygous rare variants in the DARS2 gene (NM_018122.4: c.1762C > G and NM_018122.4: c.563G > A; p.(Leu588Val) and p.(Arg188Gln), respectively). The variants were predicted as pathogenic using three pathogenicity prediction tools (SIFT [5], PolyPhen-2 [6] and MutationTaster [7]). The variant c.1762C > G (rs972404343) was reported as “likely pathogenic” in the ClinVar database [8]; it was absent from both the ExAC and gnomAD databases [9]. The second variant, c.563G > A (rs182811621), was not reported in the ClinVar database but had very low allele frequencies in the ExAC and gnomAD databases (0.00001 and 0.000004, respectively) [9]. Sanger sequencing (Fig. 2) identified the father and mother as heterozygous carriers of the single variant c.1762C > G and c.563G > A, respectively, and validated the presence of both variants in patients 2043 and 2044. Additionally, subject 2042, who had only mild signs on examination, was found to harbor both variants.
To further investigate the genotype-phenotype correlation as well as the association between the clinical and radiological findings, brain and spinal MRIs were obtained for patient 2042. Interestingly, she presented similar features to her affected siblings in the form of periventricular white matter, dentate nuclei, medulla oblongata and cervical spinal cord areas of signal changes and cerebral and spinal cord atrophic changes (Fig. 1). Biochemical investigations showed an elevated serum lactate level (reference range: 0.5–2.2 mmol/L) in patients 2043 and 2044 (6.8 mmol/L and 5.97 mmol/L, respectively) and in patient 2042 (6.13 mmol/L) as well. Currently, the younger patients are on regular physiotherapy. No further medical intervention has been undertaken in the minimally affected elder sister.

Discussion and conclusion

Compound heterozygous mutations are implicated in the majority of LBSL cases [10]. There is a wide variety in the clinical presentation of patients [10]. In addition, there is no apparent genotype-phenotype correlation nor is there a correlation between the degree of mitochondrial aspartyl-tRNA synthetase dysfunction and disease severity [11]. In this report, we showed that patients in the same family with the same compound heterozygous mutations can vary in their clinical presentations from an apparently healthy individual (with findings limited to brisk reflexes incidentally recognized at age 20 years) to disabled patients. Additionally, we highlighted the marked dissociation that can occur between clinical phenotype and MRI findings in LBSL. To the best of our knowledge, such a dissociation has only previously been reported in two sisters diagnosed with asymptomatic LBSL due to compound heterozygous mutations in DARS2 [12]. On the other hand, the dissociation between clinical and radiological phenotypes has been reported in other forms of leukodystrophies [13, 14]. However, the biological basis of this dissociation has yet to be unraveled. In our opinion biochemical, radiological or genetic screening of healthy siblings of LBSL patients could be of value to rule out the presence of the disease. Detecting asymptomatic/minimally symptomatic patients is of value in premarital counseling, especially in countries where consanguineous marriage is common. Studies that are more comprehensive could determine the sensitivity, specificity and cost-effectiveness of such screening methods. Our study is the first to report cases of LBSL from sub-Saharan Africa. Nevertheless, functional studies are still needed to confirm the pathogenicity of the reported variants.
In conclusion, LBSL can show marked phenotypic variability even within the same family. This variable expressivity may complicate the detection of the causative variants in the context of genetic counseling.

Acknowledgements

Not applicable.

Funding

This study was financially supported by the Agence Nationale pour la Recherche (to GS), the European Union (H2020, to GS) and the E-rare program (to GS). AY is a recipient of a Campus France and University of Khartoum fellowship. MAS was supported by the Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia, via research group project number RGP-VPP-301. The funding bodies had no role in the design of the study, in the collection, analysis and interpretation of data or in writing the manuscript.

Availability of data and materials

Data (not including participants’ personal information or identifiers) are available from the corresponding author upon reasonable request.
The study was approved by the Ethics committee of Paris-Necker Hospital (France) and the Ethics Committee of the University of Khartoum Medical Campus (Sudan). All participants agreed to participate in the study. Written informed consent was obtained from each patient and healthy family member before participation in the study. For participants under the age of 18, written informed consents were obtained from their father.
Signed informed consents were obtained from participants for publication of personal and medical details included in the case report. For participants under the age of 18, signed consent for publication was obtained from their father.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Van Der Knaap MS, Van Der Voorn P, Barkhof F, Van Coster R, Krägeloh-Mann I, Feigenbaum A, et al. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol. 2003;53(2):252–8.CrossRef Van Der Knaap MS, Van Der Voorn P, Barkhof F, Van Coster R, Krägeloh-Mann I, Feigenbaum A, et al. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol. 2003;53(2):252–8.CrossRef
2.
Zurück zum Zitat van Berge L, Hamilton EM, Linnankivi T, Uziel G, Steenweg ME, Isohanni P, et al. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain. 2014;137(Pt 4):1019–29.CrossRef van Berge L, Hamilton EM, Linnankivi T, Uziel G, Steenweg ME, Isohanni P, et al. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain. 2014;137(Pt 4):1019–29.CrossRef
3.
Zurück zum Zitat Scheper GC, van der Klok T, van Andel RJ, van Berkel CGM, Sissler M, Smet J, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007;39(4):534–9.CrossRef Scheper GC, van der Klok T, van Andel RJ, van Berkel CGM, Sissler M, Smet J, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007;39(4):534–9.CrossRef
4.
Zurück zum Zitat Aradjanski M, Dogan SA, Lotter S, Wang S, Hermans S, Wibom R, et al. DARS2 protects against neuroinflammation and apoptotic neuronal loss, but is dispensable for myelin producing cells. Hum Mol Genet. 2017;26(21):4181–9.CrossRef Aradjanski M, Dogan SA, Lotter S, Wang S, Hermans S, Wibom R, et al. DARS2 protects against neuroinflammation and apoptotic neuronal loss, but is dispensable for myelin producing cells. Hum Mol Genet. 2017;26(21):4181–9.CrossRef
5.
Zurück zum Zitat Sim N-L, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40(Web Server issue):W452–7.CrossRef Sim N-L, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40(Web Server issue):W452–7.CrossRef
6.
Zurück zum Zitat Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013 Jan;Chapter 7:Unit7.20. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013 Jan;Chapter 7:Unit7.20.
7.
Zurück zum Zitat Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.CrossRef Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.CrossRef
8.
Zurück zum Zitat Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980–5.CrossRef Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980–5.CrossRef
9.
Zurück zum Zitat Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 2017;45(D1):D840–5.CrossRef Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 2017;45(D1):D840–5.CrossRef
10.
Zurück zum Zitat Finsterer J, Zarrouk-Mahjoub S. Phenotypic spectrum of DARS2 mutations. J Neurol Sci. 2017;376:117–8.CrossRef Finsterer J, Zarrouk-Mahjoub S. Phenotypic spectrum of DARS2 mutations. J Neurol Sci. 2017;376:117–8.CrossRef
11.
Zurück zum Zitat van Berge L, Kevenaar J, Polder E, Gaudry A, Florentz C, Sissler M, et al. Pathogenic mutations causing LBSL affect mitochondrial aspartyl-tRNA synthetase in diverse ways. Biochem J. 2013;450(2):345–50.CrossRef van Berge L, Kevenaar J, Polder E, Gaudry A, Florentz C, Sissler M, et al. Pathogenic mutations causing LBSL affect mitochondrial aspartyl-tRNA synthetase in diverse ways. Biochem J. 2013;450(2):345–50.CrossRef
12.
Zurück zum Zitat Labauge P, Dorboz I, Eymard-Pierre E, Dereeper O, Boespflug-Tanguy O. Clinically asymptomatic adult patient with extensive LBSL MRI pattern and DARS2 mutations. J Neurol. 2011;258(2):335–7.CrossRef Labauge P, Dorboz I, Eymard-Pierre E, Dereeper O, Boespflug-Tanguy O. Clinically asymptomatic adult patient with extensive LBSL MRI pattern and DARS2 mutations. J Neurol. 2011;258(2):335–7.CrossRef
13.
Zurück zum Zitat Di Bella D, Pareyson D, Savoiardo M, Farina L, Ciano C, Caldarazzo S, et al. Subclinical leukodystrophy and infertility in a man with a novel homozygous CLCN2 mutation. Neurology. 2014;83(13):1217–8.CrossRef Di Bella D, Pareyson D, Savoiardo M, Farina L, Ciano C, Caldarazzo S, et al. Subclinical leukodystrophy and infertility in a man with a novel homozygous CLCN2 mutation. Neurology. 2014;83(13):1217–8.CrossRef
14.
Zurück zum Zitat Abrams CK, Scherer SS, Flores-Obando R, Freidin MM, Wong S, Lamantea E, et al. A new mutation in GJC2 associated with subclinical leukodystrophy. J Neurol. 2014;261(10):1929–38.CrossRef Abrams CK, Scherer SS, Flores-Obando R, Freidin MM, Wong S, Lamantea E, et al. A new mutation in GJC2 associated with subclinical leukodystrophy. J Neurol. 2014;261(10):1929–38.CrossRef
Metadaten
Titel
Intra-familial phenotypic heterogeneity in a Sudanese family with DARS2-related leukoencephalopathy, brainstem and spinal cord involvement and lactate elevation: a case report
verfasst von
Ashraf Yahia
Liena Elsayed
Arwa Babai
Mustafa A. Salih
Sarah Misbah El-Sadig
Mutaz Amin
Mahmoud Koko
Rayan Abubakr
Razaz Idris
Shaimaa Omer M.A. Taha
Salah A. Elmalik
Alexis Brice
Ammar Eltahir Ahmed
Giovanni Stevanin
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Neurology / Ausgabe 1/2018
Elektronische ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-018-1180-7

Weitere Artikel der Ausgabe 1/2018

BMC Neurology 1/2018 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.